

Giampiero Girolomoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1700072/publications.pdf>

Version: 2024-02-01

293
papers

14,170
citations

26630

56
h-index

26613

107
g-index

299
all docs

299
docs citations

299
times ranked

12516
citing authors

#	ARTICLE	IF	CITATIONS
1	A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1146-1149.	2.2	19
2	Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 68-73.	0.9	53
3	Hypochondriasis and Personality Traits of Patients with Chronic Plaque Psoriasis. <i>Dermatology</i> , 2022, 238, 276-282.	2.1	1
4	Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 80-85.	1.3	5
5	Unmet needs in atopic dermatitis management: an expert consensus. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2459-2465.	2.2	7
6	Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 165-167.	1.3	23
7	Predictors of subsequent primary melanoma: a case-control study. <i>Archives of Dermatological Research</i> , 2022, 314, 881-885.	1.9	1
8	Primary nodular localized cutaneous amyloidosis of the scalp associated with systemic lupus erythematosus. <i>Archives of Rheumatology</i> , 2022, 37, 145-147.	0.9	5
9	Skin adverse reactions to Sars-CoV-2 vaccination: a relevant responsibility issue for dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 165-166.	2.4	1
10	Flare management in atopic dermatitis: from definition to treatment. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232110667.	2.5	13
11	Biological agents targeting interleukin-13 for atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 651-659.	3.1	8
12	Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1277-1288.	3.3	26
13	Biological agents targeting interleukin-13 for atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.2	7
14	Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare. <i>JAMA Dermatology</i> , 2022, 158, 375.	4.1	35
15	The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases. <i>Italian Journal of Dermatology and Venereology</i> , 2022, , .	0.2	0
16	Dermoscopic features of nevoid melanoma: a retrospective study with systematic literature review. <i>Italian Journal of Dermatology and Venereology</i> , 2022, , .	0.2	0
17	Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	0
18	Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, 1-78.	0.2	25

#	ARTICLE	IF	CITATIONS
19	Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi TM): a multidisciplinary perspective. Expert Opinion on Biological Therapy, 2022, 22, 109-121.	3.1	7
20	Upadacitinib in patients with resistant atopic dermatitis: a retrospective case series. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1499-1500.	2.4	8
21	Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis. Expert Opinion on Biological Therapy, 2022, 22, 1579-1584.	3.1	6
22	Contact allergy in children with and without atopic dermatitis: An Italian multicentre study. Contact Dermatitis, 2022, 87, 265-272.	1.4	11
23	Is risankizumab as needed administration a good option for patients with plaque psoriasis?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	3
24	Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. Vaccines, 2022, 10, 646.	4.4	5
25	Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis. Dermatology and Therapy, 2022, 12, 1303-1311.	3.0	7
26	Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. Journal of Clinical Medicine, 2022, 11, 2801.	2.4	6
27	Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192-weeks multicentric retrospective study (IL PSO) (Italian landscape psoriasis). Dermatologic Therapy, 2022, 35, .	1.7	10
28	Monkeypox virus infection: what dermatologist needs to know?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	10
29	Dupilumab for recalcitrant Kimura disease. Dermatologic Therapy, 2022, 35, .	1.7	8
30	Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: The Rotterdam Study. Journal of the American Academy of Dermatology, 2021, 85, 671-680.	1.2	27
31	Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. Journal of Dermatological Treatment, 2021, 32, 507-513.	2.2	67
32	The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey. Dermatology and Therapy, 2021, 11, 117-130.	3.0	37
33	<i>HLA-Cw6</i> and other HLA-C alleles, as well as <i>MICB-DT</i> , <i>DDX58</i> and <i>TYK2</i> genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Expert Opinion on Biological Therapy, 2021, 21, 259-270.	3.1	22
34	Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 958-964.	2.4	66
35	Place of apremilast in the real-life treatment of patients with plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 13-13.	2.4	3
36	Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. Acta Dermato-Venereologica, 2021, 101, adv00402.	1.3	45

#	ARTICLE	IF	CITATIONS
37	Increased red blood cell distribution width in patients with plaque psoriasis. <i>Journal of Medical Biochemistry</i> , 2021, 40, 199-201.	1.7	9
38	Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer. <i>Dermatology</i> , 2021, 237, 1-5.	2.1	9
39	IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review. <i>Dermatologic Therapy</i> , 2021, 34, e14889.	1.7	14
40	Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 581-586.	6.7	38
41	Pruritus as a Distinctive Feature of Type 2 Inflammation. <i>Vaccines</i> , 2021, 9, 303.	4.4	66
42	Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1813-1824.	5.7	28
43	Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e355-e357.	2.4	2
44	Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study. <i>Dermatologic Therapy</i> , 2021, 34, e14949.	1.7	4
45	Characteristics associated with clinical response to Comano thermal spring water balneotherapy in pediatric patients with atopic dermatitis. <i>Italian Journal of Pediatrics</i> , 2021, 47, 91.	2.6	1
46	Assessing patients' characteristics and treatment patterns among children with atopic dermatitis. <i>Italian Journal of Pediatrics</i> , 2021, 47, 92.	2.6	4
47	Coexistence of scleromyxedema and Sneddon syndrome. <i>JAAD Case Reports</i> , 2021, 11, 47-50.	0.8	0
48	Non-Bullous Pemphigoid: A Single-Center Retrospective Study. <i>Dermatology</i> , 2021, 237, 1039-1045.	2.1	5
49	Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04153.	0.5	5
50	The pruritogenic role of the type 2 immune response in diseases associated with chronic itch. <i>Experimental Dermatology</i> , 2021, 30, 1208-1217.	2.9	10
51	Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. <i>Dermatologic Therapy</i> , 2021, 34, e15035.	1.7	24
52	Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 247-253.	3.2	22
53	Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature. <i>Case Reports in Dermatology</i> , 2021, 13, 282-288.	0.8	1
54	Impact of the COVID-19 pandemic on melanoma diagnosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e714-e715.	2.4	20

#	ARTICLE	IF	CITATIONS
55	A case of genital primary syphilis with superimposed impetigo. Italian Journal of Dermatology and Venereology, 2021, , .	0.2	0
56	Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis. Journal of the American Academy of Dermatology, 2021, , .	1.2	8
57	Reply to: Non-Bullous Pemphigoid: A Yet-to-Be Defined Disease Entity. Dermatology, 2021, 237, 1-2.	2.1	0
58	Adrenergic urticaria successfully treated with omalizumab. Journal of Dermatology, 2021, 48, e541-e542.	1.2	2
59	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatology and Therapy, 2021, 11, 235-252.	3.0	34
60	Nomenclature and clinical phenotypes of atopic dermatitis. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110029.	2.5	43
61	Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Italian Journal of Dermatology and Venereology, 2021, 156, 455-459.	0.2	2
62	Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis. Clinical Drug Investigation, 2021, 41, 1011-1020.	2.2	10
63	Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis. Journal of Personalized Medicine, 2021, 11, 1069.	2.5	4
64	Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. Journal of Clinical Medicine, 2021, 10, 5344.	2.4	58
65	Clinical profile and co-infections of urethritis in males. Italian Journal of Dermatology and Venereology, 2021, , .	0.2	1
66	The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clinical and Experimental Rheumatology, 2021, 39, 1099-1107.	0.8	2
67	Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
68	Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis. Journal of Cutaneous Medicine and Surgery, 2021, , 120347542110669.	1.2	1
69	Exfoliative cheilitis as a manifestation of factitial cheilitis in a young man. Italian Journal of Dermatology and Venereology, 2021, 156, 513-514.	0.2	1
70	A case of porokeratosis with predominant follicular involvement. Italian Journal of Dermatology and Venereology, 2021, 156, 619-620.	0.2	1
71	Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. Journal of Dermatological Treatment, 2020, 31, 794-800.	2.2	26
72	Visual Vignette. Endocrine Practice, 2020, 26, 253.	2.1	1

#	ARTICLE	IF	CITATIONS
73	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. <i>Journal of Dermatological Treatment</i> , 2020, 31, 606-614.	2.2	72
74	The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1026-1036.	2.4	52
75	Paradoxical psoriasis induced by TNF± blockade shows immunological features typical of the early phase of psoriasis development. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 55-68.	3.0	27
76	The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. <i>British Journal of Dermatology</i> , 2020, 182, 1331-1342.	1.5	102
77	Psoriasin (S100A7) is increased in the serum of patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 1502-1503.	1.5	11
78	<p>Targeting IL-4 for the Treatment of Atopic Dermatitis</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 151-156.	5.8	56
79	Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks. <i>Journal of Clinical Medicine</i> , 2020, 9, 3594.	2.4	13
80	Clinical features and treatments of transient acantholytic dermatosis (Grover's disease): a systematic review. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 826-833.	0.8	8
81	A case of kerion celsi caused by <i>Trichophyton tonsurans</i>. <i>Pediatrics International</i> , 2020, 62, 1007-1008.	0.5	3
82	Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. <i>Dermatologic Therapy</i> , 2020, 33, e14281.	1.7	12
83	Mortality from cancer is not increased in elderly kidney transplant recipients compared to the general population: a competing risk analysis. <i>Journal of Nephrology</i> , 2020, 33, 1309-1319.	2.0	4
84	Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections. <i>Vaccines</i> , 2020, 8, 517.	4.4	65
85	Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies. <i>Vaccines</i> , 2020, 8, 769.	4.4	29
86	The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. <i>Vaccines</i> , 2020, 8, 728.	4.4	27
87	Job: the prototypic dermatological patient. Comments on a painting by Marcello Fogolino. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2175-2176.	2.4	2
88	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2839-2845.	2.4	6
89	Brodalumab in the treatment of chronic plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1175-1186.	3.1	8
90	Switching from one infliximab biosimilar (CTP13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2020, 183, 397-398.	1.5	17

#	ARTICLE	IF	CITATIONS
91	Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. <i>Frontiers in Pharmacology</i> , 2020, 11, 117.	3.5	80
92	Consensus on the place in therapy of TNF- α inhibitors in the treatment of patients with chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e470-e472.	2.4	6
93	Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 39-45.	1.2	51
94	Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. <i>Dermatologic Therapy</i> , 2020, 33, e13979.	1.7	15
95	Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2499-2504.	2.4	96
96	Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab. <i>Dermatologic Therapy</i> , 2020, 33, e13967.	1.7	4
97	Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination. <i>Vaccine</i> , 2020, 38, 3808-3809.	3.8	1
98	Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 285-287.	1.2	49
99	A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 481-491.	3.1	6
100	Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 271-285.	2.3	20
101	Non-Melanoma Skin Cancer in Outdoor Workers: A Study on Actinic Keratosis in Italian Navy Personnel. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2321.	2.6	11
102	TNF- α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 591-598.	3.0	18
103	Undertreatment in adult patients with moderate-to-severe atopic dermatitis and other chronic inflammatory skin diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2168-2169.	2.4	4
104	Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21. <i>Aging</i> , 2020, 12, 6823-6851.	3.1	20
105	The burden of atopic dermatitis in adults in Italy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 19-23.	0.8	8
106	Topical tacrolimus in adult atopic dermatitis: a consensus based on a 15-year experience. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 8-13.	0.8	9
107	Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA). <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 1-7.	0.8	18
108	Amicrobial pustulosis of the folds: Report of three new cases. <i>Indian Journal of Dermatology</i> , 2020, 65, 323.	0.3	2

#	ARTICLE	IF	CITATIONS
109	Bleomycin-induced Flagellate Dermatitis: a Case Report. Serbian Journal of Dermatology and Venereology, 2020, 12, 15-18.	0.2	0
110	Nivolumab induced morphea. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 701-702.	0.8	2
111	Idiopathic lichenoid and granulomatous dermatitis. Italian Journal of Dermatology and Venereology, 2020, , .	0.2	0
112	Therapeutic management of chronic spontaneous urticaria in clinical practice: results from a pilot survey. Italian Journal of Dermatology and Venereology, 2020, , .	0.2	0
113	Chronic spontaneous urticaria in clinical practice: a pilot survey about attitudes and perceptions on assessment, diagnostic work-up and dietary management. Italian Journal of Dermatology and Venereology, 2020, , .	0.2	0
114	Lysyl oxidase-like-2 mutations and reduced mRNA and protein expression in mid-dermal elastolysis. Clinical and Experimental Dermatology, 2019, 44, 47-51.	1.3	7
115	A systematic review of treatments for pityriasis lichenoides. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2039-2049.	2.4	28
116	The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. International Journal of Molecular Sciences, 2019, 20, 3318.	4.1	91
117	Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52-weeks observation. Dermatologic Therapy, 2019, 32, e13091.	1.7	21
118	State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Current Opinion in Pharmacology, 2019, 46, 90-99.	3.5	34
119	Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission. British Journal of Dermatology, 2019, 181, 1319-1320.	1.5	8
120	Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study. Journal of the American Academy of Dermatology, 2019, 81, 403-411.	1.2	29
121	Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. British Journal of Dermatology, 2019, 182, 175-179.	1.5	3
122	Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. British Journal of Dermatology, 2019, 181, 413-414.	1.5	21
123	Relapse of psoriatic arthritis in patients with active psoriasis switched from tumour necrosis factor- α to interleukin-17A inhibitor. British Journal of Dermatology, 2019, 181, 624-626.	1.5	3
124	The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opinion on Pharmacotherapy, 2019, 20, 863-872.	1.8	23
125	Low dose acitretin versus methotrexate in the treatment of palmoplantar psoriasis: a case series. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e246-e247.	2.4	3
126	Glomerular filtration rate in patients with moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e244-e246.	2.4	4

#	ARTICLE	IF	CITATIONS
127	Etanercept biosimilar <sc>SB</sc> 4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2019, 180, 409-410.	1.5	17
128	Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel. <i>Allergologia Et Immunopathologia</i> , 2019, 47, 194-206.	1.7	11
129	BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. <i>British Journal of Dermatology</i> , 2019, 180, 933-934.	1.5	5
130	Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 918-924.	2.4	85
131	The multifaceted association between psoriasis and obesity. <i>British Journal of Dermatology</i> , 2019, 180, 24-24.	1.5	2
132	Lymphoplasmatic plaque effectively treated with imiquimod. <i>Italian Journal of Dermatology and Venereology</i> , 2019, , .	0.2	0
133	Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 133-136.	0.8	20
134	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	2.9	16
135	Interferon-beta injection site reactions in patients with multiple sclerosis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 831-834.	2.2	8
136	Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 657-682.	2.4	727
137	Classifying immunopathological responses in chronic inflammatory skin diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 654-655.	2.4	2
138	Segregation analysis revealed hemizygotic causative mutations in a pseudoxanthoma elasticum patient. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e365-e366.	2.4	0
139	Image Gallery: Pyoderma gangrenosum of the penis. <i>British Journal of Dermatology</i> , 2018, 178, e62.	1.5	0
140	Kyrle's disease effectively treated with oral isotretinoin. <i>Journal of Dermatological Treatment</i> , 2018, 29, 630-632.	2.2	7
141	Epidemiology of atopic dermatitis in adults: Results from an international survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1284-1293.	5.7	546
142	Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. <i>British Journal of Dermatology</i> , 2018, 178, e215-e216.	1.5	26
143	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. <i>British Journal of Dermatology</i> , 2018, 178, 768-775.	1.5	127
144	Psoriasis and the metabolic syndrome. <i>Clinics in Dermatology</i> , 2018, 36, 21-28.	1.6	211

#	ARTICLE	IF	CITATIONS
145	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 515-528.	2.4	15
146	Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. Journal of Dermatological Treatment, 2018, 29, 217-219.	2.2	30
147	Analisi di budget impact del biosimilare di etanercept: lo scenario italiano. Global & Regional Health Technology Assessment, 2018, 2018, 228424031876680.	0.1	3
148	Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis. Journal of Immunology Research, 2018, 2018, 1-18.	2.2	32
149	Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics: Targets and Therapy, 2018, Volume 12, 151-158.	3.2	18
150	Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 850-878.	2.4	519
151	Pediatric CD8+/CD56+ mycosis fungoides with cytotoxic marker expression: A variant with indolent course. Journal of Cutaneous Pathology, 2018, 45, 782-785.	1.3	9
152	The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Frontiers in Immunology, 2018, 9, 1549.	4.8	279
153	A Reappraisal on the Potential Ability of Human Neutrophils to Express and Produce IL-17 Family Members In Vitro: Failure to Reproducibly Detect It. Frontiers in Immunology, 2018, 9, 795.	4.8	49
154	Back to the future: a new topical approach for mild-to-moderate psoriasis. Italian Journal of Dermatology and Venereology, 2018, 153, 375-382.	0.2	9
155	Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches. Expert Opinion on Investigational Drugs, 2018, 27, 699-707.	4.1	1
156	Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. Medical Ultrasonography, 2018, 20, 177.	0.8	23
157	Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study. European Journal of Dermatology, 2018, 28, 44-49.	0.6	14
158	The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. Current Medical Research and Opinion, 2017, 33, 993-1003.	1.9	25
159	Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 863-869.	2.4	31
160	Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 774-790.	2.4	140
161	Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. British Journal of Dermatology, 2017, 177, e325-e326.	1.5	19
162	Primary Cutaneous CD4 ⁺ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series. Journal of Cutaneous Medicine and Surgery, 2017, 21, 502-506.	1.2	14

#	ARTICLE	IF	CITATIONS
163	Public perception of dermatology and dermatologists in Italy: results from a population-based national survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2119-2123.	2.4	16
164	European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 228-241.	0.8	20
165	Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin. <i>Journal of Dermatology</i> , 2017, 44, e332-e333.	1.2	0
166	Role of MyD88 signaling in the imiquimod-induced mouse model of psoriasis: focus on innate myeloid cells. <i>Journal of Leukocyte Biology</i> , 2017, 102, 791-803.	3.3	23
167	Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis. <i>Npj Biofilms and Microbiomes</i> , 2017, 3, 14.	6.4	159
168	The role of IL-23 and the IL-23/Th17 immune axis in the pathogenesis and treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1616-1626.	2.4	187
169	European consensus-based (S2k) Guideline on the Management of Herpes Zoster "guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)", Part 1: Diagnosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 9-19.	2.4	62
170	Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. <i>Journal of Dermatological Treatment</i> , 2017, 28, 390-393.	2.2	7
171	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 294-303.	2.4	12
172	European consensus-based (S2k) Guideline on the Management of Herpes Zoster "guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)", Part 2: Treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 20-29.	2.4	125
173	Experimental metagenomics and ribosomal profiling of the human skin microbiome. <i>Experimental Dermatology</i> , 2017, 26, 211-219.	2.9	34
174	Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. <i>European Journal of Dermatology</i> , 2017, 27, 599-608.	0.6	30
175	Public perception of dermatology and dermatologists: a very relevant but untapped issue. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1950-1950.	2.4	4
176	Treatment Approaches to Moderate to Severe Psoriasis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2427.	4.1	96
177	Advanced Glycation End Products in the Pathogenesis of Psoriasis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2471.	4.1	43
178	Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis. <i>Acta Dermato-Venereologica</i> , 2017, 97, 782-787.	1.3	30
179	A cream based on <i>Aquaphilus dolomiae</i> extracts alleviates non-histaminergic pruritus in humans. <i>European Journal of Dermatology</i> , 2017, 27, 317-318.	0.6	18
180	Cutaneous manifestations of adult-onset Still's disease: a case report and review of literature. <i>Clinical Rheumatology</i> , 2016, 35, 1377-1382.	2.2	35

#	ARTICLE	IF	CITATIONS
181	Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1763.	4.3	26
182	Clinical features and course of cutaneous mastocytosis in 133 children. <i>British Journal of Dermatology</i> , 2016, 174, 411-413.	1.5	13
183	Lysyl oxidase-like 2 promoter hypermethylation in mid-dermal elastolysis. <i>British Journal of Dermatology</i> , 2016, 175, 1354-1356.	1.5	5
184	Italian expert consensus for the management of actinic keratosis in immunocompetent patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1077-1084.	2.4	41
185	Treatment of psoriasis with etanercept: the typical patient profile. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1092-1099.	2.4	17
186	Metastatic Crohn's disease in childhood. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 431-434.	0.8	9
187	Metastatischer Morbus Crohn in der Kindheit. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 431-434.	0.8	7
188	Fusidic acid betamethasone lipid cream. <i>International Journal of Clinical Practice</i> , 2016, 70, 4-13.	1.7	9
189	Heat urticaria: a revision of published cases with an update on classification and management. <i>British Journal of Dermatology</i> , 2016, 175, 473-478.	1.5	32
190	Non-alkoholic fatty liver disease fibrosis score in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 282-287.	2.4	50
191	Single organ cutaneous vasculitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2016, 34, 6561-6571.	3.8	6
192	Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report. <i>Journal of International Medical Research</i> , 2016, 44, 109-112.	1.0	7
193	Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 305-311.	3.4	12
194	European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1657-1669.	2.4	43
195	Considerations for Systemic Treatment of Psoriasis in Obese Patients. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 609-615.	6.7	40
196	Glomerular filtration rate in patients with psoriasis treated with etanercept. <i>Journal of International Medical Research</i> , 2016, 44, 106-108.	1.0	8
197	Keratosis lichenoides chronica: Case-based review of treatment options. <i>Journal of Dermatological Treatment</i> , 2016, 27, 383-388.	2.2	12
198	Vasculitis as an adverse event following immunization – Systematic literature review. <i>Vaccine</i> , 2016, 34, 6641-6651.	3.8	87

#	ARTICLE	IF	CITATIONS
199	Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. <i>Vaccine</i> , 2016, 34, 6634-6640.	3.8	41
200	Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2016, 151, 432-5.	0.8	3
201	Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2002-2010.	2.4	139
202	A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2390-2398.	2.4	23
203	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). <i>British Journal of Dermatology</i> , 2015, 173, 1387-1399.	1.5	384
204	AB0821...Baseline Characteristics of Patients with Moderate to Severe Psoriatic Arthritis: Post-Hoc Analysis of Responders vs Non-Responders to Etanercept. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1174-1174.	0.9	1
205	Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2399-2404.	2.4	104
206	Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. <i>British Journal of Dermatology</i> , 2015, 172, 1613-1620.	1.5	36
207	Intralymphatic Histiocytosis: A case report and review of literature. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 593-599.	1.3	20
208	The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2411-2416.	2.4	16
209	Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities. <i>Frontiers in Medicine</i> , 2015, 2, 1.	2.6	68
210	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , 2015, 14, 864-874.	5.8	25
211	Facial basal cell carcinomas treated with hypo-fractionated radiotherapy: A retrospective analysis in 117 elderly patients. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 166-168.	1.2	12
212	Chromatin remodelling and autocrine TNF α are required for optimal interleukin-6 expression in activated human neutrophils. <i>Nature Communications</i> , 2015, 6, 6061.	12.8	87
213	Skin moisturization for xerosis related to targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e33.	1.2	0
214	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 167-182.	4.4	46
215	Experimental elicitation of itch: Evoking and evaluation techniques. <i>Journal of Dermatological Science</i> , 2015, 80, 13-17.	1.9	8
216	Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. <i>Journal of Dermatological Treatment</i> , 2015, 26, 103-112.	2.2	50

#	ARTICLE	IF	CITATIONS
217	Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 27-36.e1.	1.2	171
218	Concept of Remission in Chronic Plaque Psoriasis. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 57-60.	2.2	15
219	Histiocytoid Sweet syndrome is infiltrated predominantly by M2-like macrophages. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 131-139.	1.2	30
220	Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel. <i>Journal of Dermatological Treatment</i> , 2015, 26, 128-133.	2.2	14
221	Biosimilar infliximab: an expert view. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2015, 150, 449-59.	0.8	4
222	The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 1-10.	2.1	69
223	Adalimumab in the Treatment of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 33-48.	2.1	65
224	Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 11-32.	2.1	50
225	Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. <i>British Journal of Dermatology</i> , 2014, 170, 591-598.	1.5	51
226	Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 22-32.	2.4	22
227	Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common comorbidities in patients with moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1661-1669.	2.4	36
228	Preheated autologous serum skin test in localized heat urticaria. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 921-923.	1.3	7
229	Hyperuricemia in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 127-130.	1.2	45
230	The Cost Effectiveness of Biologic Therapy for the Treatment of Chronic Plaque Psoriasis in Real Practice Settings in Italy. <i>BioDrugs</i> , 2014, 28, 285-295.	4.6	20
231	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. <i>Autoimmunity Reviews</i> , 2014, 13, 751-755.	5.8	67
232	Skin rash and arthritis a simplified appraisal of less common associations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 679-688.	2.4	10
233	The Role of Interleukin-17A in Psoriatic Disease. <i>BioDrugs</i> , 2014, 28, 487-497.	4.6	37
234	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	1.2	423

#	ARTICLE	IF	CITATIONS
235	Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2014, 149, 607-25.	0.8	7
236	Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e30-41.	2.4	75
237	Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. <i>Immunologic Research</i> , 2013, 56, 382-389.	2.9	46
238	Survival rate of antitumour necrosis factor- α treatments for psoriasis in routine dermatological practice: a multicentre observational study. <i>British Journal of Dermatology</i> , 2013, 169, 666-672.	1.5	138
239	Tongue flap to treat a severe case of Miescher's cheilitis granulomatosa. <i>Minerva Stomatologica: A Journal on Dentistry and Maxillofacial Surgery</i> , 2013, 62, 79-86.	1.3	1
240	Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF α agents. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 889-897.	0.8	42
241	Interstitial granulomatous dermatitis: a distinct entity with characteristic histological and clinical pattern. <i>British Journal of Dermatology</i> , 2012, 166, 775-783.	1.5	99
242	Psoriasis: rationale for targeting interleukin-17. <i>British Journal of Dermatology</i> , 2012, 167, 717-724.	1.5	120
243	Medikamenteninduzierter Lupus erythematosus unter besonderer Berücksichtigung von Hautmanifestationen und Anti-TNF α -Therapeutika. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 889-897.	0.8	20
244	Safety of anti-TNF α agents in the treatment of psoriasis and psoriatic arthritis. <i>Immunopharmacology and Immunotoxicology</i> , 2012, 34, 548-560.	2.4	41
245	Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2012, 147, 609-24.	0.8	12
246	Cutaneous manifestations of Churg-Strauss syndrome: report of two cases and review of the literature. <i>Clinical Rheumatology</i> , 2011, 30, 573-580.	2.2	45
247	Subcutaneous sarcoidosis: report of two cases and review of the literature. <i>Clinical Rheumatology</i> , 2011, 30, 1123-1128.	2.2	42
248	Patients with Psoriasis Have a Higher Prevalence of Parental Cardiovascular Disease. <i>Dermatology</i> , 2011, 222, 330-335.	2.1	11
249	Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. <i>Oncologist</i> , 2011, 16, 228-238.	3.7	94
250	Cost-effectiveness analysis of TNF α blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. <i>Dermatologic Therapy</i> , 2010, 23, S7-S13.	1.7	17
251	C-Reactive Protein and Markers for Thrombophilia in Patients with Chronic Plaque Psoriasis. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 1195-1202.	2.1	31
252	Urticarial lesions: If not urticaria, what else? The differential diagnosis of urticaria. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 541-555.	1.2	58

#	ARTICLE	IF	CITATIONS
253	Urticarial lesions: If not urticaria, what else? The differential diagnosis of urticaria. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 557-570.	1.2	57
254	Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1785-1796.	0.7	554
255	Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. <i>Autoimmunity</i> , 2010, 43, 215-219.	2.6	72
256	Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. <i>Dermatology</i> , 2009, 219, 158-161.	2.1	6
257	Psoriasis and Atherothrombotic Diseases: Disease-Specific and Non-“Disease-Specific Risk Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 313-324.	2.7	86
258	Drug-induced lupus erythematosus. <i>Archives of Dermatological Research</i> , 2009, 301, 99-105.	1.9	221
259	Psoriasis and systemic inflammation: underdiagnosed enthesopathy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 3-8.	2.4	57
260	Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. <i>Journal of Hepatology</i> , 2009, 51, 758-764.	3.7	217
261	Perception of Disease and Doctor-Patient Relationship Experienced by Patients with Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 325-330.	6.7	39
262	Anti-“tumour necrosis factor” therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 341-344.	2.4	166
263	Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 742-750.	5.7	211
264	Drug-induced morphea: Report of a case induced by balicatib and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 125-129.	1.2	106
265	Targeting tumor necrosis factor \pm in psoriasis and psoriatic arthritis. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1085-1096.	3.4	58
266	Psoriasis and Metabolic Comorbidities: The Importance of Well-Designed Prospective Studies. <i>Dermatology</i> , 2008, 217, 222-224.	2.1	8
267	Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 26-30.	0.9	249
268	Focus on psoriatic arthritis and comorbidities. <i>Expert Review of Dermatology</i> , 2008, 3, S35-S36.	0.3	2
269	Contact allergy in chronic eczematous lip dermatitis. <i>European Journal of Dermatology</i> , 2008, 18, 688-92.	0.6	35
270	Cutaneous necrosis complicating the injection of pegylated interferon alpha-2b in a patient with chronic hepatitis C. <i>Acta Dermatovenerologica Croatica</i> , 2008, 16, 35-7.	0.1	5

#	ARTICLE	IF	CITATIONS
271	Prurigo pigmentosa in a pregnant woman. International Journal of Gynecology and Obstetrics, 2007, 98, 261-262.	2.3	15
272	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. British Journal of Dermatology, 2007, 157, 68-73.	1.5	543
273	Biologic therapies in psoriasis: A new therapeutic approach. Autoimmunity Reviews, 2007, 6, 515-519.	5.8	83
274	Keratinocytes in skin inflammation. Expert Review of Dermatology, 2006, 1, 279-291.	0.3	18
275	Autoimmune progesterone dermatitis. Gynecological Endocrinology, 2006, 22, 54-56.	1.7	30
276	The contribution of keratinocytes to the pathogenesis of atopic dermatitis. European Journal of Dermatology, 2006, 16, 125-31.	0.6	100
277	Pimecrolimus in dermatology: atopic dermatitis and beyond. International Journal of Clinical Practice, 2005, 59, 969-974.	1.7	47
278	Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. European Journal of Dermatology, 2005, 15, 279-83.	0.6	73
279	Prevalence of symptoms experienced by patients with different clinical types of psoriasis. British Journal of Dermatology, 2004, 151, 594-599.	1.5	174
280	Subacute Cutaneous Lupus Erythematosus Induced by Nifedipine. Journal of Cutaneous Medicine and Surgery, 2003, 7, 243-246.	1.2	14
281	The epidemiology of atopic dermatitis in Italian schoolchildren. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 420-425.	5.7	74
282	Subacute Cutaneous Lupus Erythematosus Induced by Nifedipine. Journal of Cutaneous Medicine and Surgery, 2003, 7, 243-246.	1.2	23
283	Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. European Journal of Immunology, 2001, 31, 812-822.	2.9	246
284	Interleukin-17 is Produced by Both Th1 and Th2 Lymphocytes, and Modulates Interferon- γ - and Interleukin-4-Induced Activation of Human Keratinocytes. Journal of Investigative Dermatology, 2000, 115, 81-87.	0.7	256
285	Keratosis lichenoides chronica. Dermatology, 2000, 201, 261-264.	2.1	15
286	IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. Journal of Immunology, 1999, 162, 494-502.	0.8	254
287	Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. Journal of Clinical Investigation, 1997, 99, 3009-3017.	8.2	183
288	Kaposi's sarcoma with primary bone lesions in an HIV-seronegative man. British Journal of Dermatology, 1996, 134, 966-969.	1.5	6

#	ARTICLE	IF	CITATIONS
289	Distribution of HLA class II molecules in epidermal Langerhans cells in situ. <i>European Journal of Immunology</i> , 1995, 25, 520-525.	2.9	35
290	Modulation of cytokine expression in mouse dendritic cell clones. <i>European Journal of Immunology</i> , 1994, 24, 2522-2526.	2.9	46
291	Congenital Dermatofibrosarcoma Protuberans. <i>Pediatric Dermatology</i> , 1993, 10, 40-42.	0.9	39
292	Phosphatidylserine enhances the ability of epidermal Langerhans cells to induce contact hypersensitivity. <i>Journal of Immunology</i> , 1993, 150, 4236-43.	0.8	15
293	Pemphigus vulgaris Following Cobalt Therapy for Bronchial Carcinoma. <i>Dermatology</i> , 1989, 178, 37-38.	2.1	14